Zum Inhalt springen


  1. Srivastava A, Santagostino E, Dougall A, et al. WFH guideline for the management of hemophilia, 3rd edition. Haemophilia. 2020;00:1-158.
  2. Nathwani AC, Reiss UM, Tuddenham EGD, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371:1994-2004.
  3. Rangarajan S, Walsh L, Lester W, et al. AAV5-Factor VII Gene Transfer in Severe Hemophilia A. N Engl J Med. 2017;377(26):2519-2530.
  4. Berntorp E, Fischer K, Hart DP, et al. Haemophilia. Nat Rev Dis Primers. 2021;7:45.
  5. National Organization for Rare Disorders (NORD). Rare Disease Database-Hemophilia B. Accessed October 27, 2021.
  6. National Organization for Rare Disorders (NORD). Rare Disease Database-Hemophilia A. Accessed October 27, 2021.
  7. University of Rochester Medical Center. Factor VIII. Accessed November 30, 2021.
  8. Mancuso ME, Santagostino E. Outcome of clinical trials with new extended half-life FVIII/IX concentrates. J Clin Med. 2017;6,39.
  9. Morfini M. The history of clotting factor concentrates pharmacokinetics. J Clin Med. 2017;6,35.
  10. European Medicines Agency (EMA). BeneFIX. https://www.ema.europa.eu/en/medicines/human/EPAR/benefix. Accessed November 30, 2021.
  11. European Medicines Agency (EMA). ReFacto AF. https:www.ema.europa.eu/en/medicines/human/EPAR/refacto-af. Accessed November 30, 2021.
  12. Hemophilia Federation of America (HFA). Bleeding Disorders Historical Timeline. https://www.hemophiliafed.org/updated-historical-timeline/. Accessed November 10, 2021.
  13. New measures needed to protect U.S. blood supply from future threats posed by infectious diseases. [press release]. Washington DC, USA: The National Academies of Sciences, Engineering, and Medicine. https://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=4989. Published July 13, 1995.
  14. Nathwani AC, Tuddenham EGD, Rangarajan S, et al. Adenovirus-Associated Virus Vector-Mediated Gene Transfer in Hemophilia B. N Engl J Med. 2011;365(25):2357-2365.
  15. Heinz S, Braspenning J. Measurement of blood coagulation factor synthesis in cultures of human hepatocytes. Methods Mol Biol. 2015;1250:309-16.
  16. Ay C, Feistritzer C, Rettl J, et al. Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Australia. Sci Rep. 2021;11(1):12967.
  17. Chhabra A, Spurden D, Fogarty PF, et al. Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B. Blood Coagul Fibrinolysis. 2020;31(3):186-192.
  18. Perrin GQ, Herzog RW, Markusic DM. Update on clinical gene therapy for hemophilia. Blood. 2019;133(5):407-414.
  19. Pool JG, Hershgold EJ, Pappenhagen AR. High-potency Antihaemophilic Factor Concentrate Prepared from Cryoglobulin Precipitate. Nature. 1964;203:312.
  20. Kasper CK, Kipnis SA. Hepatitis and clotting-factor concentrates. 1972;221(5):510.
  21. White GC. Hemophilia: an amazing 35-year journey from the depths of HIV to the threshold of cure. Trans Am Clin Climatol Assoc. 2010;121:61-75.
  22. European Medicines Agency (EMA). Elcota. https://www.ema.europa.eu/en/medicines/human/EPAR/elocta. Accessed October 30, 2021.
  23. European Medicines Agency (EMA). AlprolIX. https://www.ema.europa.eu/en/medicines/human/EPAR/alprolix. Accessed October 30, 2021.